Skip to content
Open access

Amplicon-based DNA and RNA unified NGS for enhanced fusion variant detection in suboptimal real-world NSCLC FFPE specimens

Aug 2026 · Translational Oncology · Vol 72, pp. 102955 · 0 citations · 36 references
Medicine

TL;DR

Unified DNA+RNA amplicon NGS delivered guideline-relevant biomarkers from 759 real-world NSCLC FFPE samples, including small biopsies and cytology, suggesting that a single low-input assay can often replace sequential DNA→RNA testing and reduce repeat biopsies.

Abstract

Highlights • Unified DNA+RNA amplicon NGS delivered guideline-relevant biomarkers from 759 real-world NSCLC FFPE samples, including small biopsies and cytology.• High success rates (>95%) across all specimen types suggest that a single low-input assay can often replace sequential DNA→RNA testing and reduce repeat biopsies.• Robust performance in 5–8-year archived FFPE samples (≥96% success) enables treatment decisions even when only old tissue blocks are available.• D+R NGS confirmed 99.3% of known fusions/exon-skipping events and rescued additional actionable alterations that would otherwise be missed by standard workflows.• Detecting 18.2% more targetable fusions in DNA-NGS–negative cases has the potential to change first-line treatment selection from empirical chemo/chemo-immunotherapy to matched TKIs.

Read PDF

Similar papers

Open access Aug 2026

Real-world performance of next-generation sequencing in advanced non-squamous non-small cell lung cancer in Brazil.

Laboratory workflow optimization, particularly the adoption of hybrid-capture methodology, significantly improved NGS success rates in a nationwide nsNSCLC testing program, highlighting the need for targeted education and infrastructural investment to broaden equitable access to precision oncology in Brazil.

B. Araújo, R. Paes, A. Rodrigues et al. · 0 citations
Open access Sep 2026

High‐Concordance Detection Across Diverse Biospecimens EGFR Mutation in a Large‐Scale NSCLC Cohort Using Droplet Digital PCR and Next‐Generation Sequencing

Accurate detection and quantification of EGFR mutations are essential for molecular stratification in non‐small cell lung cancer (NSCLC). While next‐generation sequencing (NGS) enables comprehensive genomic profiling, droplet digital PCR (ddPCR) offers high sensitivity for predefined mutations. Large‐scale evaluati...

Ming Liu, Lin-Ping Lu, Qifang Lei et al. · 0 citations
Oct 2026

B-088 Comprehensive Genomic Profiling of Solid Tumors by Next Generation Sequence : Clinical Utility and Biomarker Discovery in a Pan-Cancer Cohort

The transition from single-gene testing to comprehensive genomic profiling (CGP) is essential for precision oncology. The next generation sequence platform, enables the simultaneous detection of diverse variants and complex immuno-oncology biomarkers, providing a holistic view of the tumor genomic landscape....

Chung-Gue Huang, Shu-Li Yang, Chang-Fu Kuo et al. · 0 citations
Open access Aug 2026

Highly Accurate Detection of Circulating Tumor DNA for Monitoring Minimal Residual Disease in Solid Tumors: Analytical and Clinical Validation of the Haystack MRD Assay.

Advances in cell-free DNA (cfDNA) processing and error-suppressed next-generation sequencing (NGS) have enabled detection of circulating tumor DNA (ctDNA) at low abundance for assessment of minimal residual disease (MRD). MRD testing requires high analytical specificity near the stochastic limit of rare-molecule sampli...

M. Clark, R. Prathapam, K. Bramlett et al. · 0 citations
Open access Sep 2026

A novel one-step multiplex PCR method (OS-MPCR) for efficient NGS library preparation in cancer

Background Next-generation sequencing (NGS) is essential for precision oncology, yet its clinical implementation is often hindered by limited sample quantity, complex workflows, and cross-contamination risks. We evaluated a modified One-Step Multiplex PCR (OS-MPCR) assay designed to streamline library construction whil...

Hai-Yan Feng, Xiao Hu, Lei Zhang et al. · 0 citations
Open access Sep 2026

Using cell free DNA (cfDNA) and RNA (cfRNA) in the diagnosis and monitoring of primary and metastatic CNS tumors

LCx using combined DNA and RNA NGS testing of CSF is a reliable approach that yields potentially practice-changing clinical information, and suggests that LBx using combined DNA and RNA NGS testing of CSF is a reliable approach that yields potentially practice-changing clinical information.

M. Albitar, Ahmad Charifa, Sally Agersborg et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.